Johnson & Johnson (JNJ) news

Older JNJ news events, each with the realized, point-in-time move the market made — page 7 of 10. Back to the JNJ overview → · Full JNJ reaction history →

Latest news

Recent JNJ events, each with its measured reaction. (Page 7 of 10.)

DateHeadlineEventSource5-minTo close
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter ResultsPress releaseBusiness Wire+0.09%-0.47%
CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 studyPress releasePR Newswire+0.09%-0.47%
Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment optionsPress releasePR Newswire-0.23%+0.21%
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myelomaPress releasePR Newswire-0.23%+0.21%
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myelomaPress releasePR Newswire-0.23%+0.21%
TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myelomaPress releasePR Newswire-0.23%+0.21%
Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)Press releasePR Newswire-0.29%+0.03%
Oshi Health Welcomes Rebecca Bennett as Vice President of Strategic Partnerships & Network OperationsPress releasePR Web-0.29%+0.03%
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitorPress releasePR Newswire-0.41%-0.83%
Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of TherapyPress releaseCanada Newswire-0.41%-0.83%
Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual MeetingPress releasePR Newswire-0.33%-0.55%
Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline resultsPress releasePR Newswire-0.33%-0.55%
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease studyPress releasePR Newswire-0.13%-0.46%
Form 13F-HR JOHNSON & JOHNSON For: Sep 30SEC filing · Form 13F-HRSEC EDGAR+0.10%-0.85%
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's diseasePress releasePR Newswire+0.15%-1.22%
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myelomaPress releasePR Newswire-0.28%-0.97%
Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024Press releasePR Newswire-0.37%-1.20%
Adapting IRT Resupply Algorithms to Balance Risk and Cost, Upcoming Webinar Hosted by XtalksPress releasePR Web-0.71%+0.49%
Codoxo Welcomes Ted Pitynski as Vice President, Head of Sales to Drive Growth for AI-Driven Payment Integrity SolutionsPress releasePR Web-0.03%-0.08%
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's diseasePress releasePR Newswire+0.08%+0.19%
New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasisPress releasePR Newswire-0.24%-1.71%
Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych CongressPress releasePR Newswire-0.03%-0.81%
Form 10-Q JOHNSON & JOHNSON For: Sep 29SEC filing · Form 10-QSEC EDGAR-0.03%-0.81%
Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & JohnsonPress releaseBusiness Wire-0.57%+0.30%
Form 8-K JOHNSON & JOHNSON For: Oct 15SEC filing · Form 8-KSEC EDGAR+1.02%+3.21%
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024Press releaseBusiness Wire+1.02%+3.21%
Johnson & Johnson Reports Q3 2024 ResultsPress releaseBusiness Wire+1.02%+3.21%
Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 studyPress releasePR Newswire+1.02%+3.21%
Johnson & Johnson to Participate in the Stifel 2024 Healthcare ConferencePress releaseBusiness Wire+0.20%-0.32%
TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitisPress releasePR Newswire-0.37%-0.53%
Johnson & Johnson Completes Acquisition of V-WavePress releaseBusiness Wire-0.08%+0.46%
Chicago Court Upholds $45 Million Mesothelioma Verdict Against Johnson & JohnsonPress releaseBusiness Wire-0.03%+0.23%
Johnson & Johnson to Participate in the Guggenheim Global Healthcare ConferencePress releaseBusiness Wire-0.39%-0.45%
ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancerPress releasePR Newswire-0.32%-0.21%
Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not plannedPress releasePR Newswire-0.62%-0.27%
Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any LightingPress releasePR Newswire-0.18%+0.30%
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second linePress releasePR Newswire-0.18%+0.30%
DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not plannedPress releasePR Newswire-0.01%-0.56%
DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myelomaPress releasePR Newswire-0.01%-0.56%
GSI, Inc. is Thrilled to Bring Cutting-Edge JD Edwards Solutions and AI-Driven Innovations to INFOCUS 2024!Press releasePR Web-0.05%-0.86%
Novel combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary diseaPress releasePR Newswire+0.04%-0.23%
TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myelomaPress releasePR Newswire+0.04%-0.23%
Attorneys Vow to Oppose J&J’s Third Bankruptcy AttemptPress releaseBusiness Wire-0.37%-0.72%
Form 8-K JOHNSON & JOHNSON For: Sep 20SEC filing · Form 8-KSEC EDGAR-0.37%-0.72%
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc ClaimsPress releaseBusiness Wire+0.09%+0.06%
Prevent Blindness Names Howard Purcell, O.D., New England College of Optometry, as the 2025 Person of Vision Award RecipientPress releasePR Web+0.05%-0.76%
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancerPress releasePR Newswire-0.21%-0.09%
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancerPress releasePR Newswire+0.55%+0.44%
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancerPress releasePR Newswire+0.55%+0.44%
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancerPress releasePR Newswire+0.55%+0.44%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground